Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;9(Suppl 1):S197-S206.
doi: 10.21037/tcr.2019.08.29.

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients

Ignacio Morales-Orue  1   2   3 , Juan Zafra-Martin  3 , Laura Garcia  3 , Rodolfo Chicas-Sett  3 , Juan Castilla-Martinez  3 , Maria Auxiliadora Cabezon  3 , Javier Burgos  4 , Marta Lloret  3 , Pedro C Lara  4   5
Affiliations
Review

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients

Ignacio Morales-Orue et al. Transl Cancer Res. 2020 Jan.

Abstract

Breast cancer (BC) is the principal cause of cancer-related death in women. Metastatic patients are usually treated with a systemic therapy, but clinical results are limited. Oligometastatic subjects can benefit from high-precision radiotherapy techniques to potentially achieve a complete response. Currently, there is limited evidence of stereotactic ablative radiotherapy (SABR) treatments in elderly oligometastatic cancer patients. A review of the medical literature was performed in PubMed database to assess the current role of SABR in the treatment of breast oligometastases in elderly patients. SABR represents a feasible and safe therapeutic approach in oligometastatic elderly BC patients. Further studies are required to establish the optimum patient selection and treatment scheme.

Keywords: Stereotactic ablative radiotherapy (SABR); breast; elderly; oligometastatic; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.08.29). The series “Radiotherapy for Breast Cancer in Advanced Age” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Liver SABR. An 80-year-old patient with single liver metastatic lesion from breast primary tumor. SABR treatment was performed by VMAT, 4D-TC scan and tracking (Calypso System). Prescribed dose was 60 Gy in 5 fractions. SABR, stereotactic ablative radiotherapy.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. 10.3322/caac.21262 - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2013. National Cancer Institute. Available online: http://seer.cancer.gov/csr/1975_2013. Accessed May 15th, 2017.
    1. Malmgren JA, Mayer M, Atwood MK, et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat 2018;167:579-90 10.1007/s10549-017-4529-5 - DOI - PMC - PubMed
    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10 10.1200/JCO.1995.13.1.8 - DOI - PubMed
    1. Oh D, Ahn YC, Seo JM, et al. Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol 2012;51:596-602. 10.3109/0284186X.2012.681698 - DOI - PubMed